Goals of Treatment Aligning With Continuum of Disease and Impact of First-Line Choices
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Jennifer A. Woyach, MD – Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center
08:35 - 08:55 CEST
Individualizing First-Line Treatment Choice Based on Patient and Disease Characteristics
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Nitin Jain, MD – The University of Texas MD Anderson Cancer Center
08:55 - 09:10 CEST
Panel Discussion With Interactivity and Audience Q&A
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
09:10 - 09:20 CEST
(1442) NGS-Based MRD Assessment Refines Prognostication After Venetoclax-Based First-Line Combinations for Chronic Lymphocytic Leukemia: A Prospective Analysis of the Phase 3 GAIA/CLL13 Trial
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Moritz Fürstenau, MD – Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
09:20 - 09:25 CEST
(1438) Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Thomas Chatzikonstantinou, MD – Institute of Applied Biosciences, Centre for Research and Technology Hellas
09:25 - 10:40 CEST
Session 6: How I Treat Double Relapsed/Refractory CLL
How Do I Treat Double Refractory Patients With Cellular Therapy?
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Philip Thompson, MB, BS (Hons) – Peter MacCallum Cancer Centre & Royal Melbourne Hospital; The Sir Peter MaCallum Department of Clinical Oncology, University of Melbourne
10:10 - 10:25 CEST
Panel Discussion With Interactivity and Audience Q&A
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
10:25 - 10:30 CEST
(1440) Transcriptional Reprogramming and Survival Co-Dependencies of Chronic Lymphocytic Leukemia Resistant to Venetoclax
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Deepa Sampath, PhD – University of Texas MD Anderson Cancer Center
10:30 - 10:35 CEST
(1441) A functional prognostic model predicts progression free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Current and Future Management of Richter Transformation
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Othman Al-Sawaf, MD PhD – Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
12:35 - 12:45 CEST
Panel Discussion With Interactivity and Audience Q&A
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
12:45 - 12:55 CEST
(1607) MGA Loss drives cristae remodeling and redox adaptation via MICOS and PRDX2 in Richters transformation
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Prajish S. Iyer, PhD – Department of Systems Biology, Beckman Research Institute, City of Hope
12:55 - 13:05 CEST
(1606) Epcoritamab Monotherapy in Patients with First-Line Richter’s Transformation: 2-Year Follow-Up Results From the Phase 1b/2 EPCORE CLL-1 Clinical Trial
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Arnon P. Kater, MD, PhD – Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, and HOVON
13:05 - 13:55 CEST
Lunch
13:05 - 13:55 CEST
Lunch
Location: ICE, Foyer 0, Level 0
13:55 - 14:55 CEST
Industry Supported Symposium Platinum Sponsor
13:55 - 14:55 CEST
Industry Supported Symposium
Location: ICE, Theater Hall (S2), Entrances On Level 0 & 1
13:55 - 14:55 CEST
Industry Supported Symposium: Innovative Approaches in CLL: Tailoring Treatment to Transform Patient Outcomes
13:55 - 14:55 CEST
Industry Supported Symposium: Innovative Approaches in CLL: Tailoring Treatment to Transform Patient Outcomes
Location: ICE, Theater Hall (S2), Entrances On Level 0 & 1
15:00 - 15:45 CEST
Session 8: Health Maintenance for Patients With CLL
Panel Discussion With Interactivity and Audience Q&A
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
15:40 - 15:45 CEST
(1717) MVA-Based GEO-CM04S1 Vaccine Results in Improved Cellular Immune Response in Patients With Chronic Lymphocytic Leukemia (CLL) Compared With mRNA-Based Vaccine: Initial Results of a Phase II Randomized Study
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Alexey V. Danilov, MD, PhD – Department of Hematology and Transplantation, City of Hope National Medical Center
15:45 - 15:55 CEST
Binet/Rai Medal Presentation
15:45 - 15:55 CEST
Binet/Rai Medal Presentation
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1